Nancy Lee retweeted
Sharing our latest in @AmJClinOncol!
Does how far a patient lives from a cancer center influence whether they receive radiation—and what type?
We studied this in people with WHO grade 2–3 meningioma.
Proud of @gorantla_nipun for leading this work!
pubmed.ncbi.nlm.nih.gov/4289…
Nancy Lee retweeted
📜 Our latest in @JAMANetworkOpen, led by @AdvaitThaploo @KaitlynLapen @FumikoChino
Financial Toxicity Among Disaggregated Asian American Cancer Survivors
Are we missing important disparities by grouping Asian Americans together?
Our data say YES
🔗 jamanetwork.com/journals/jam…
Nancy Lee retweeted
Excellent, must-read summary of the TORPEdO and MDACC trials
Incredibly proud of Sudarshan Ramanan @sramanan03, @George_Ashji, and team who led our newly published commentary in @JCO_ASCO!
A remarkable achievement and a testament to the team's leadership, intellectual curiosity, and hard work.
🔗 ascopubs.org/doi/10.1200/JCO…
Nancy Lee retweeted
#ProtonBeamTherapy has received so much visibility in recent times so this issue in the RedJ @ASTRO_org is timely edited by @sueyom Dave Carlson
Thanks for the opportunity to share our experience with PBT for #NasopharyngealCarcinoma @NCCS_SG where we have treated ~250 patients to date 💪💪 We share specific scenarios where PBT is efficacious and where caution must be exercised @lachiemcd @imrtlee @mikemejiamd @seanmmcbride @xrtGenomics @DavidSherMD @DrDThomson @EChrisDee @emmaruoyii
Free link to the article below!
sciencedirect.com/science/ar…
Nancy Lee retweeted
Incredibly proud of Sudarshan Ramanan @sramanan03, @George_Ashji, and team who led our newly published commentary in @JCO_ASCO!
A remarkable achievement and a testament to the team's leadership, intellectual curiosity, and hard work.
🔗 ascopubs.org/doi/10.1200/JCO…
Excited to share our latest paper in the Journal of Clinical Oncology. Grateful to my co-authors
@EChrisDee, @imrtlee, @seanmmcbride, @xrtGenomics, @george_ashji, Eric Sherman, Khoi Nguyen, and Danil Ratnikov
@MSKCancerCenter @MSK_RadOnc @JCO_ASCO
ascopubs.org/doi/10.1200/JCO…
Nancy Lee retweeted
Speaking at @statnews summit today on future of cancer research @UTMDAnderson. Congrats to @adam_grippin for being named a Statwunderkind! #endcancer
Nancy Lee retweeted
Our commentary @IJROBP on virtual care in #radonc in response to @CShahMD's thoughtful piece.
A few points to emphasize. A brief 🧵
First, it is important to define the regulatory landscape and separate two concepts that are too often collapsed: supervised technical services versus the radiation oncologist’s personal performance of professional services.
Radoncs supervise the services delivered by RTTs. When we talk about supervision, this is the type of activity that is being supervised.
In contrast, evaluating, adjusting, and signing CBCTs prior to SBRT, on-treatment management, plan evaluations, etc are the professional services radoncs perform.
An important threshold question: does federal law permit virtual supervision and virtual performance of professional activities?
sciencedirect.com/science/ar…
Nancy Lee retweeted
V different diseases, but working with @imrtlee taught me that maybe if good response we don’t need the full dose escalation🤔if no GTV after neoadj ADT —> is 36 Gy enough? If doesn’t respond —> is 42 (eg should we push 45+)?
Nancy Lee retweeted
@PierluigiBonomo thanks for getting all of us together in beautiful Firenze! ❤️❤️❤️🇮🇹
#FlorenceConsensus26
@Qle_stanford @imrtlee @sueyom @PBlanchardMD @piet_ost @BrigetteMa2 @mikemejiamd @ChadTangMD
Nancy Lee retweeted
The @FDA recently approved a targeted therapy called lirafugratinib (Lyrfigtu) for people with advanced cholangiocarcinoma (bile duct cancer) that has a genetic change called an FGFR2 fusion or an FGFR2 rearrangement.
The clinical trial that resulted in the drug’s approval was led by MSK early drug development specialist Dr. @AliSchram.
“Cholangiocarcinoma is a rare cancer that is almost always caught after it has spread, making it extremely challenging to treat,” Dr. Schram says. “Any time we find a new treatment for patients with this disease, it can make a meaningful difference to them and their families.”
Learn more about this approval: bit.ly/4hZw319
Nancy Lee retweeted
Et tu, Nads?
It’ll take more than free Espresso to poach our All-Star faculty @UTMDAnderson. You’re gonna have to offer baked goods, too.
#ASTRO26 @MSK_RadOnc @xrtGenomics @imrtlee
Nancy Lee retweeted
Based only on these 3 slides :), it looks like no difference in tox but, at least for HPV negative dz, you have significantly more failures in the weekly Cis regimen. The CI for the LRF difference between the two regimens in the HPV negative population doesn't cross 0. Reinforces our local practice of q 3 weekly Cis. Maybe I'm missing something....
Nancy Lee retweeted
Seems like there is a notable separation early on. Still need to follow up longer for both p16+ and p16- groups to see durable LRF results.
@DavidSherMD @Qle_stanford
Nancy Lee retweeted
🌎👋@NRGonc #HN009 p16-neg #ASTRO26; Dr. Paul Harari @UWMadison
➡️Diff AE profiles b/w Q1 vs Q3
➡️6 mo LRF diff 5% (Q1 9.6% & Q3 4.6%; 95%CI 1.0-8.9) Longer FU needed.
@DanielMaMD @quyhnhi99 @imrtlee @JamesBatesMD
@JJCaudell @drlorenmell @seanmmcbride @xrtGenomics
@ASTRO_org
Nancy Lee retweeted
So proud of Dr. Dave Fuller for being recognized with the #ASTRO26 mentorship award. He has impacted generations of students, trainees, and faculty. @utmdanderson #endcancer
Nancy Lee retweeted
No difference in overall survival with protons vs photons in OPC! Great work by our APP Ying! @imrtlee @seanmmcbride @yaoyu @CJTsaiMDPhD #astro26 #hncsm #radonc
Nancy Lee retweeted
Fame is how widely you are known (can be known for good or bad things). Legacy is what remains because you were here.
Fame is largely about attention in the present. It can come from achievement, celebrity, visibility, wealth, or simply being associated with a major event. It is often measured by how many people know your name?
Legacy is about enduring impact. It asks: What did you change? Who did you influence? What institutions, ideas, discoveries, people, or values continued after you? A person can have enormous legacy without ever being particularly famous.
Always chase impact. Change the way the world does things whether they know your name or not.
Pick any medical specialty other than your own. Who’s the most famous physician in it? You probably can’t name one.
Almost none of us will be known outside our field, and even those who achieve real professional fame are mostly forgotten within a few decades.
Fame is a poor reason to devote your life to medicine. The work itself matters more: caring for patients, discovering new knowledge, and teaching the next generation.
Nancy Lee retweeted
🚨👀Interested in #metastasis #oligomet #polymet #MDT? You can't miss this session at 5pm ‼️
➡️SBRT for abdom oligomet @WashUMedRadOnc
➡️Sim-free RT
➡️Prophy bone-met RT
➡️Sub-ablative SBRT w/ ICI
➡️AI/ML modeling @lthoon0420
#ASTRO26 @ASTRO_org @AmyXuMDPhD @RadMedPM @Mat_Guc
Nancy Lee retweeted
Today at #ASTRO26: MSK radiation oncologist @alexgoglia will present five-year outcomes from a trial of MR-guided SBRT with a focal DIL boost for intermediate-risk prostate cancer.
🗓️ Monday, September 28 | 3:10 p.m. ET
Learn more: bit.ly/47lXHPT
